1,4-bis{3,4-bis[3-(piperidin-1-yl)propoxy]phenyl}-butane | 1018685-49-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1,4-bis{3,4-bis[3-(piperidin-1-yl)propoxy]phenyl}-butane
• 英文别名: 1,4-Bis(3,4-bis[3-(piperidin-1-yl)propoxy]phenyl}-butane；1-[3-[4-[4-[3,4-bis(3-piperidin-1-ylpropoxy)phenyl]butyl]-2-(3-piperidin-1-ylpropoxy)phenoxy]propyl]piperidine
• CAS: 1018685-49-8
• 化学式: C₄₈H₇₈N₄O₄
• 分子量: 775.172
• InChiKey: XLDDJVSPMYRZIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.1
• 重原子数：
  56
• 可旋转键数：
  25
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  49.9
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,4-bis{3,4-bis[3-(piperidin-1-yl)propoxy]phenyl}-butane 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以83.2%的产率得到1,4-bis{3,4-bis[3-(piperidin-1-yl)propoxy]phenyl}-butane tetrakis-hydrochloride salt
  参考文献：
  名称：

  WO2008/42921

  摘要：

  公开号：
• 作为产物：
  描述：

  4-溴黎芦醚 在 三溴化硼 、 potassium carbonate 、 magnesium 、 sodium iodide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 40.0h， 生成 1,4-bis{3,4-bis[3-(piperidin-1-yl)propoxy]phenyl}-butane
  参考文献：
  名称：

  WO2008/42921

  摘要：

  公开号：

文献信息

• TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE
  申请人：Heller Jonathan Daniel

  公开号：US20090306070A1

  公开（公告）日：2009-12-10

  The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

  本发明涉及诺地酚酸衍生物化合物，即丁烷桥修饰的诺地酚酸（NDGA）化合物和丁烷桥修饰的四-O-取代诺地酚酸化合物，包含它们的药物组合物，制备它们的方法以及使用它们的方法和包括它们的工具包，用于治疗疾病和障碍，特别是由病毒感染引起或与之相关的疾病，如HIV感染，HPV感染或HSV感染，炎症性疾病，如各种类型的关节炎和炎症性肠病，代谢性疾病，如糖尿病和高血压，或增殖性疾病，如各种类型的癌症。
• Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use
  申请人：Heller Jonathan Daniel

  公开号：US08691845B2

  公开（公告）日：2014-04-08

  The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

  本发明涉及诺地酚酸衍生物化合物，即丁烷桥修饰的诺地酚酸（NDGA）化合物和四个-O-取代的丁烷桥修饰的NDGA化合物，以及含有它们的制药组合物，制备它们的方法，以及使用它们和包括它们的工具箱治疗疾病和疾病的方法和工具箱，特别是由病毒感染引起或与之相关的疾病，如HIV感染，HPV感染或HSV感染，炎症性疾病，如各种类型的关节炎和炎症性肠病，代谢性疾病，如糖尿病和高血压，或增殖性疾病，如不同类型的癌症。
• TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMAECUTICAL USE
  申请人：Heller Jonathan Daniel

  公开号：US20140221384A1

  公开（公告）日：2014-08-07

  The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

  本发明涉及一种诺迪羟基愈创木酸衍生物化合物，即丁烷桥修饰的诺迪羟基愈创木酸（NDGA）化合物和丁烷桥修饰的四-O-取代NDGA化合物，包含它们的药物组合物、制备它们的方法以及使用它们的方法和包括它们的用于治疗疾病和疾病的工具包，特别是由病毒感染引起或与之相关的疾病，如HIV感染、HPV感染或HSV感染，炎症性疾病，如各种类型的关节炎和炎症性肠病，代谢性疾病，如糖尿病和高血压，或增殖性疾病，如各种类型的癌症。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。
• Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US11147800B2

  公开（公告）日：2021-10-19

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。